Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist
description
Transcript of Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist
![Page 1: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/1.jpg)
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist
Hagop M. Kantarjian, MDChairman; Professor, Department of LeukemiaUniversity of Texas, MD Anderson Cancer CenterHouston, Texas
Jorge E. Cortes, MDChair, CML Section, Division of Cancer MedicineUniversity of Texas, Department of Leukemia, MD Anderson Cancer CenterHouston, Texas
Ronjay Rakkhit, MDOncology ConsultantsHouston, Texas
William S. Velasquez, MDAllopathic & Osteopathic Physicians Internal Medicine Hematology & OncologyHouston, Texas
![Page 2: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/2.jpg)
• It accounts for 0.34% of all cancers, 3.6% of hematologic malignancies, and 0.08% of all cancer mortality.[a]
• 5050 new cases were estimated in the United States in 2009, and 470 people with CML were estimated to die in the same time period.[a]
• From 2003 to 2007, age-adjusted incidence rates of the disease were 2.0 per 100,000 men and 1.1 per 100,000 women.[b]
CML: Epidemiology
a. Jemal A, et al. CA Cancer J Clin. 2009;59:225-249.b. NCI/SEER. Available at: http://seer.cancer.gov/statfacts/html/cmyl.html
![Page 3: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/3.jpg)
• Myeloproliferative disorder of the primitive hematopoietic stem cell[a]
• Arises from a translocation t(9;22)(q34;q11), known as the Philadelphia chromosome[a]
• Resulting bcr-abl1 fusion gene codes for a constitutively active tyrosine kinase[a,b]
CML: Pathophysiology
a. Kantarjian H, et al. Blood. 1993;82:691-703.b. Quintás-Cardama A, Cortés JE. Blood. 2009;113:1619-1630.
![Page 4: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/4.jpg)
• Most cases are diagnosed in the chronic phase (CP).[a]
• Before the advent of imatinib therapy, the median survival was approximately 3-4 years.[b]
• The advent of imatinib changed the natural history of CML.[c]
CML: Advent of Imatinib
a. Faderl S, et al. N Engl J Med. 1999;341:164-172.b. Kantarjian H, et al. Cancer. 2008;113(suppl):1933-1952.c. Weisberg E, et al. Nat Rev Cancer. 2007;7:345-356.
![Page 5: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/5.jpg)
CML: FDA-Approved Second-line TKIs
Weisberg E, et al. Nat Rev Cancer. 2007;7:345-356.
![Page 6: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/6.jpg)
CML: IRIS Trial 5- and 8-Year Follow-up[a]
a. Druker BJ, et al. N Engl J Med. 2003;355:2408-2417.b. Deininger M, et al. ASH 2009. Abstract 1126.
• At 8 years, estimated overall survival was 85%, and 93% when only CML-related deaths were considered.[b]
![Page 7: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/7.jpg)
Appropriate in Patients With Suspected CML at Diagnosis?
Bone Marrow Analysis in the Community Setting
![Page 8: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/8.jpg)
May Provide Information About Additional Chromosomal Abnormalities and Number of Blasts
Appropriate and Important in Patients With Suspected CML at Diagnosis
Bone Marrow Analysis in the Community Setting
![Page 9: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/9.jpg)
Patients With Newly Diagnosed CML-CPNilotinib vs Imatinib: Phase 3 ENESTnd Trial
Larson RA, et al. ASCO 2010. Abstract 6501.
Rate of progression to AP/BC CML •Nilotinib 300 mg BID: 0.7% (P = .006 vs imatinib) •Nilotinib 400 mg BID: 0.4% (P = .003 vs imatinib) •Imatinib 400 mg QD: 4.2%
Response (%)
Nilotinib 300 mg BID
(n = 282)
Nilotinib 400 mg BID
(n = 281)
Imatinib 400 mg QD
(n = 283)MMR• At 12 mo (ITT) 44* 43* 22• At 18 mo (n = 525) 69 63 36• At 24 mo (n = 145) 86 88 48CCyR• At 12 mo (ITT) 80* 78† 65• At 18 mo (n = 442) 99 99 89
*P < .0001 vs imatinib†P < .001 vs imatinib
![Page 10: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/10.jpg)
Patients With Newly Diagnosed CML-CPDasatinib vs Imatinib: Phase 3 DASISION Trial
Kantarjian H, et al. ASCO 2010. LBA6500.
Dasatinib IMn (%) P
CCyR (≥ 20 metaphases) 3 mo 140 (54) 80 (31) 6 mo 189 (73) 154 (59) 12 mo 216 (83) 186 (72) .0011MMR 3 mo 21 (8) 1 (<1) 6 mo 70 (27) 21 (8) 12 mo 119 (46) 73 (28) < .0001
![Page 11: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/11.jpg)
Which Method, When, and How Often?
Optimal Monitoring in the Community Practice
![Page 12: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/12.jpg)
• Identify patient with suboptimal response early– Do not wait until the patient loses hematologic response• Intervene early
– Optimize dose– Change therapy– Increase probability of good response and long-term
favorable outcome
Frequent MonitoringImportance and Rationale
Patients With Cytogenetic Relapse Typically Respond Better to Second-Generation TKIs Than Patients With Hematologic Relapse.
![Page 13: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/13.jpg)
Imatinib FailureOperational Criteria
Baccarani M, et al. J Clin Oncol. 2009;27:6041-6051.CCA = clonal chromosome abnormalities
Evaluation Time (mo) FailureBaseline NA3 Less than CHR6 No CyR (Ph + > 95%)12 Less than PCyR (Ph + > 35%)18 Less than CCyR
Any time during treatment Loss of CHR; loss of CCyR; mutations; CCA/PH+
![Page 14: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/14.jpg)
Intervene or Just Monitor and Continue With The Same Treatment?
Patient in CCyR With Rising Q-PCR
![Page 15: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/15.jpg)
Value of Any Intervention Is Unknown; Keep Monitoring
Patient in CCyR With Rising Q-PCR
![Page 16: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/16.jpg)
ComplianceMajor Effect on Response
Marin D, et al. J Clin Oncol. 2010;28:2381-2388.
![Page 17: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/17.jpg)
If Dose Is Reduced Earlier, Try Optimizing Dose
Patient in CCyR With Rising Q-PCR
![Page 18: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/18.jpg)
Monitoring CMLProposed Approach
Kantrajian H, et al. Blood. 2008;111:1774-1780.
![Page 19: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/19.jpg)
Second-, Third-, or Occasionally First-line Therapy?
Role of Allogeneic Transplant Today
![Page 20: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/20.jpg)
Rarely a First-line Therapy Even in Patients in Accelerated or Blastic Phase or Those Who
Failed to Respond to Imatinib (Except in Patients With T315I Mutation)
Role of Allogeneic Transplant Today
![Page 21: Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist](https://reader035.fdocuments.in/reader035/viewer/2022062501/56815dd2550346895dcbfe41/html5/thumbnails/21.jpg)
• Omacetaxine (homoharringtonine)• AP24534• DCC230326
Patients With T315I MutationEmerging Therapies